Twist Bioscience prices upsized $300 million stock offering, closes August 6

Twist Bioscience Corporation announced on August 4, 2026 the start of an underwritten public offering originally sized at $250.0 million of common stock, with an option for underwriters to buy up to an additional $37.5 million of shares within 30 days.¹

The offering was upsized and priced the same day. Under the underwriting agreement, Twist agreed to sell 3,125,000 shares to the underwriters at a public offering price of $96.00 per share, before underwriting discounts and commissions.¹ The underwriters also received a 30-day option to buy up to 468,750 additional shares.¹ That option was exercised in full the next day: on August 5, 2026, the underwriters purchased all 468,750 additional shares at the same $96.00 price, less discounts and commissions.¹

With the option exercised, Twist expects net proceeds of about $327.1 million once underwriting discounts, commissions and estimated offering expenses are subtracted.¹ The offering is set to close on or about August 6, 2026, subject to customary closing conditions.¹

Twist said it plans to direct the proceeds, combined with cash on hand, toward research and development, manufacturing capacity growth, and other product initiatives, reserving the remainder for working capital and general corporate needs, as described in the offering documents. Goldman Sachs & Co. LLC, William Blair, Leerink Partners and Guggenheim Securities served as joint book-running managers for the deal. The shares were offered under an automatic shelf registration statement on Form S-3 filed with the SEC on June 18, 2026, which became effective upon filing.¹